INVESTABOT
Equity Research
XNAS · BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) · BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Amgen (AMGN) had 1 Form 144 pre-sale notice filed on 2026-08-13. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Amgen (AMGN) had 1 Form 144 pre-sale notice filed on 2026-05-04. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
TL;DR: Amgen announced CFO Peter Griffith's retirement after six years in the role, with Thomas Dittrich set to take over as CFO on September 1, 2026. The transition is planned and structured, with Griffith staying throu…
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 8/13/2026 | Khosla Rachna | SVP, Business Development | OPTION_EXERCISE | 1,252 | $163 | $203,575 |
| 8/13/2026 | Khosla Rachna | SVP, Business Development | SELL | -1,252 | $416 | $521,365 |
| 8/13/2026 | Khosla Rachna | SVP, Business Development | OPTION_EXERCISE | -1,252 | — | — |
| 8/11/2026 | Khosla Rachna | SVP, Business Development | SELL | -2,000 | $413 | $825,134 |
| 8/7/2026 | Drake Michael V | — | GRANT | 63.88 | — | — |
| 8/7/2026 | ISHRAK OMAR | — | GRANT | 85.17 | — | — |
| 8/7/2026 | HOLLEY CHARLES M | — | GRANT | 103.42 | — | — |
| 8/7/2026 | Busch Matthew C. | VP, Finance & CAO | GRANT | 730 | — | — |
| 8/6/2026 | Miller Derek | SVP, Human Resources | OPTION_EXERCISE | 2,069 | $163 | $336,419 |
| 8/6/2026 | Miller Derek | SVP, Human Resources | SELL | -2,069 | $403 | $832,864 |
| 8/6/2026 | Miller Derek | SVP, Human Resources | OPTION_EXERCISE | 1,821 | $177 | $323,155 |
| 8/6/2026 | Miller Derek | SVP, Human Resources | SELL | -1,821 | $403 | $733,033 |
| 8/6/2026 | Miller Derek | SVP, Human Resources | OPTION_EXERCISE | -2,069 | — | — |
| 8/6/2026 | Miller Derek | SVP, Human Resources | OPTION_EXERCISE | -1,821 | — | — |
| 8/6/2026 | Grygiel Nancy A. | SVP & CCO | OPTION_EXERCISE | 1,970 | $177 | $349,596 |
| 8/6/2026 | Grygiel Nancy A. | SVP & CCO | SELL | -1,970 | $402 | $792,255 |
| 8/6/2026 | Grygiel Nancy A. | SVP & CCO | OPTION_EXERCISE | 1,000 | $177 | $177,310 |
| 8/6/2026 | Grygiel Nancy A. | SVP & CCO | SELL | -1,000 | $402 | $402,160 |
| 8/6/2026 | Grygiel Nancy A. | SVP & CCO | OPTION_EXERCISE | -1,970 | — | — |
| 8/6/2026 | Grygiel Nancy A. | SVP & CCO | OPTION_EXERCISE | -1,000 | — | — |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| Vanguard Group | 54,838,826 | $17,949,296,138 | — | 1/29/2026 |
| BlackRock | 49,362,016 | $17,874,973,549 | 4.8% | 8/7/2026 |
| BlackRock | 47,100,472 | $16,572,301,125 | -0.6% | 5/13/2026 |
| BlackRock | 47,396,138 | $15,513,229,833 | — | 2/12/2026 |
| BlackRock | 46,042,729 | $14,386,050,803 | — | 8/13/2024 |
| State Street | 30,560,537 | $11,066,581,658 | 0.0% | 8/7/2026 |
| State Street | 30,548,488 | $10,748,485,503 | -0.1% | 5/15/2026 |
| State Street | 30,591,403 | $10,012,872,116 | — | 2/13/2026 |
| Morgan Stanley | 15,836,058 | $5,571,918,344 | 0.6% | 5/15/2026 |
| Morgan Stanley | 15,744,528 | $5,153,342,607 | — | 5/27/2026 |
| Morgan Stanley | 13,653,692 | $4,944,276,009 | -13.8% | 8/13/2026 |
| JP Morgan Chase | 7,437,937 | $2,595,840,786 | 212.0% | 5/13/2026 |
| Goldman Sachs | 4,559,332 | $1,651,025,290 | 3.2% | 8/14/2026 |
| Goldman Sachs | 4,417,289 | $1,554,223,141 | -4.0% | 5/15/2026 |
| Goldman Sachs | 4,600,358 | $1,505,743,070 | — | 3/25/2026 |
| JP Morgan Chase | 3,971,184 | $1,431,811,325 | -46.6% | 8/12/2026 |
| Fidelity (FMR) | 3,776,430 | $1,328,736,908 | 5.1% | 5/15/2026 |
| Fidelity (FMR) | 3,491,822 | $1,264,458,692 | -7.5% | 8/13/2026 |
| Fidelity (FMR) | 3,592,220 | $1,175,769,605 | — | 2/17/2026 |
| Citadel Advisors | 2,469,384 | $894,213,335 | 59.9% | 8/14/2026 |